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Abstract OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) in obese children is a 
diagnostic challenge. The enhanced liver fibrosis test (ELF) based on the combina-
tion of serum concentration of hyaluronic acid (HA), aminoterminal propeptide 
of type III procollagen (PIIINP), tissue inhibitor of matrix metalloproteinase 
type 1 (TIMP-1) was developed as a noninvasive diagnostic tool for estimation of 
degree of liver fibrosis. The aim of our study was to investigate the performance 
of ELF test in obese children with ultrasound-proven steatosis in order assess the 
possibility of early detection of fibrotic changes in liver structure. 
MATERIAL AND METHODS: 58 obese (BMI >95th percentile) children, 27 male 
(mean age 13.9±2.65 years) and 31 female (mean age 13.82±2.64 years). Based 
on the liver ultrasound (US) examination results two groups of obese children 
were studied: group with steatosis (N=20, 8/12 M/F, mean age 14.2±1.90 years, 
BMI 32.9±5.60 kg/m2) and group with normal liver US (n=38, 19/19 M/F, mean 
age 13.7±2.94 years, BMI 30.4±4.67 kg/m2). Serum activity of aminotransferases 
(AST, ALT) and lactate dehydrogenase (LDH), and γ-glutamyl transpeptidase 
(GGT), and ELF test (HA, PIIINP, and TIMP-1 were analyzed. 
RESULTS: Children with liver steatosis presented with significantly higher AST 
(34.1 vs. 25.6 U/L), ALT (43.4 vs. 32 U/L), LDH (427.5 vs. 361.3 U/L), GGT (30.7 
vs. 18.9 U/L). The ELF test value was also significantly higher in that group (8.98 
vs. 8.49). Nevertheless no combination of measured parameters with ELF test 
value show better diagnostic value for differentiation between children with and 
without steaotosis. 
CONCLUSION: ELF test cannot be used for assessment of steatosis in obese children. 
INTRODUCTION
Obesity is a growing worldwide problem in gen-
eral population so prevention from serious conse-
quences at early stages of this condition become 
more and more important (Moya 2008; Ogden et 
al. 2014). One of its consequences is the increas-
ing incidence of nonalcoholic fatty liver disease 
(NAFLD) (Alisi et al. 2009; Mencin & Lavine 
2011), which affects 2.6–9.8% of children and ado-
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lescents in general population (Tominaga et al. 1995; 
Franzese et al. 1997; Schwimmer et al. 2006), and up 
to 74% obese individuals (Patton et al. 2006; Papan-
dreou et al. 2007; Dunn & Schwimmer 2008; Manco et 
al. 2008). NAFLD is wide spectrum of liver pathology 
ranging from relatively benign hepatocellular steatosis 
to irreversible liver cirrhosis, caused by an accumula-
tion of triglyceride (TG) in liver cells. It is defined by 
hepatic fat infiltration of more than 5% hepatocytes 
in the absence of excessive alcohol intake, viral, auto-
immune and drug-induced liver disease (Clark et al. 
2002). Recently, NAFLD became the main cause of 
chronic liver disease in children (Day 2011; Matthies-
sen et al. 2008; Ji 2008). There is no clear clinical fea-
tures that could indicate NAFLD definitely. Moreover, 
distinguishing simple steatosis from more advances 
forms such as nonalcoholic steatohepatitis (NASH), 
nonalcoholic hepatic fibrosis and nonalcoholic cirrho-
sis in affected patient is frequently needed. NASH may 
progress towards cirrhosis also in pediatric population 
thus it is necessary to assess the stage of liver fibrosis 
(Powell et al. 1990; Molleston et al. 2002; Feldstein et 
al. 2009; Roberts 2007; Jankowska et al. 2007; Jonas et 
al. 2005). Nowadays percutaneous liver biopsy as the 
gold standard is commonly used for NAFLD diagnosis 
(Takahashi & Fukusato 2010; Neuschwander-Tetri et al. 
2010; Straub & Schirmacher 2010). However, this refer-
ence method has limitations resulted from biopsy sam-
pling variability and invasive nature of the procedure 
(Bedossa et al. 2003; Maharaj et al. 1986; Cadranel et al. 
2000; Ratziu et al. 2005; Rockey et al. 2009). Due to these 
shortcomings the development of noninvasive diagnos-
tic methods for staging the degree of fibrosis should be 
a priority, especially in pediatric population. It is even 
more important, as NALFD in pediatric patients differs 
histologically from one observed in adults (Schwimmer 
et al. 2005; Ko et al. 2009). 
The enhanced liver fibrosis (ELF) test, based on the 
combination of three direct serum markers concen-
tration measurement: hyaluronic acid (HA), amino-
terminal propeptide of type III procollagen (PIIINP), 
and tissue inhibitor of matrix metalloproteinase type 1 
(TIMP-1), is a noninvasive method designed for detec-
tion of liver fibrosis in subjects with chronic liver dis-
ease caused by different factors. However, evaluation 
of this test in children was performed only in a limited 
number of studies (Nobili et al. 2009 “a”; Nobili et al. 
2010; Iacobellis et al. 2006 ). The aim of our study was 
to investigate the performance of ELF test in obese chil-
dren with ultrasound-proven steatosis in order to check 
the usefulness of this test for early detection of fibrotic 
changes in liver structure.
MATERIALS AND METHODS
A total of 58 obese children, 27 male (mean age 
13.9±2.65 years, BMI 31.48±4.25 kg/m2) and 31 female 
(mean age 13.82±2.64 years, BMI 31.05±5.81 kg/m2), 
treated in the University Children’s Hospital in Cracow, 
Poland, were included to the study. Obesity was defined 
taking into account body mass index (BMI) value 
higher than the 95th percentile adjusted for age and 
sex of the child. Out of 58 patients 34% of children 
had steatosis proven in ultrasound examination (US). 
Based on the abdominal US results two groups of 
obese children were studied: group I (N=20, 8/12 M/F, 
mean age 14.2±1.90 years, BMI 32.9±5.60 kg/m2) with 
US proven steatosis and group II (n=38, 19/19 M/F, 
mean age 13.7±2.94 years, BMI 30.4±4.67 kg/m2) with 
normal liver US. In all patients fasting blood samples 
were taken during a planned visit in hospital. Based on 
medical history alcohol consumption, the presence of 
autoimmunologic, drug-induced or virus-induced liver 
diseases has been excluded.
Serum activity of aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), lactate dehydroge-
nase (LDH), and γ-glutamyl transpeptidase (GGT) 
were analyzed in fresh serum samples by dry chemistry 
methods (VITROS®  5.1 FS, Ortho Clinical Diagnos-
tics). For component of ELF test determination serum 
samples eres stored at –20 °C until assayed. HA, PIIINP, 
and TIMP-1 concentrations were measured separately 
on ADVIA Centaur XP (Siemens Healthcare Diagnos-
tic Inc. Tarrytown, New York USA) based on immuno-
chemiluminescence method. The concentration of HA, 
PIIINP and TIMP-1 were used for calculation of ELF 
test value using following formula: ELF=2.278+0.851 ln 
(HA)+0.751 ln (PIIINP)+0.394 ln (TIMP-1) according 
to the manufacturer instruction.
Statistical analysis
The results were expressed as the mean values with 
the standard deviation (SD). Student’s t-test or Mann-
Whitney U-test were used for between groups compari-
son The level of statistical significance was established 
at p<0.05. The areas under the ROC curves (AUROCs) 
were estimated for each enzyme measured, HA, PIIINP 
and TIMP-1 and ELF test. The data were analyzed using 
Statistica data analysis software system version 10 (Stat-
Soft, Inc. (2011), Krakow, Poland).
RESULTS
Among all children studied only in six children AST 
activity was above normal, in another 13 ALT activ-
ity was above reference range, while in nine children 
increased GGT activity was observed. Although higher 
mean values of AST, ALT and GGT activity were noted 
for boys as compared to girls, no significant differences 
in the mean values of all measured parameters between 
boys and girls were found. 
In obese children with steatosis confirmed by US 
the mean values of all enzymes activities were signifi-
cantly higher as compared to the mean values obtained 
in obese children without steatosis (Table 1). However, 
significantly higher AST and ALT activity in boys with 
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steatosis (p<0.002 and p<0.001, respectively) but not 
in girls with steatosis as compared to boys and girls 
without steatosis were noted. Although higher mean 
values of LDH activity in boys and girls with steatosis 
were observed as compared to boys and girls without 
steatosis the difference were not statistically significant. 
The mean values of GGT activity in boys (p<0.001) and 
girls (p<0.02) with steatosis were significantly higher in 
patients with steatosis as compared to patients without 
steatosis.
Among the ELF test components, the mean con-
centration values of HA and TIMP-1 were significantly 
higher in children with steatosis as compared to chil-
dren without steatosis (p<0.003 and p<0.02, respec-
tively), whereas no significant difference was noted for 
PIIINP level. Nevertheless, such differences between 
patients with and without steatosis were seen only for 
boys (p<0.002, both for HA and TIMP-1) but not for 
girls. Significantly higher mean value of ELF test was 
observed for children with steatosis as compared to 
children without steatosis (p<0.005) (Table 2). Similar 
data were obtained for boys but not for girls.
Cut-off values for liver enzymes, HA, PIIINP, 
TIMP-1 and ELF test value as well as area under ROC 
curves (AUC), sensitivity, specificity, positive and 
negative predictive values are presented in Table 3. All 
parameters measured, excluding LDH, showed similar 
specificity but low sensitivity. No combination of mea-
sured parameters with ELF test value show better diag-
nostic value for differentiation between children with 
and without steatosis. 
DISCUSSION
Invasiveness of liver biopsy used as a gold standard 
to assess degree of liver fibrosis is the main reason for 
searching new, more acceptable methods and mark-
ers. In practice noninvasive evaluation, like imaging 
techniques and liver enzyme measurement, is per-
formed to confirm the diagnosis of fatty liver disease. 




All children Boys Girls
With steatosis Without steatosis With steatosis Without steatosis With steatosis Without steatosis
AST 34.1±12.5 25.6±6.7 39.3±13.4 25.8±4.6 30.7±11.1 25.5±8.4
p<0.002 p<0.002 NS
ALT 43.4±22.6 32.0±12.1 53.5±22.8 32.0±11.1 37.5±21.2 31.9±13.2
p<0.006 p<0.001 NS
LDH 427.5±103.2 361.3±68.0 395.7±73.1 353.1±41.2 447.4±118.5 370.4±91.3
p<0.04 NS NS
GGT 30.7±12.7 18.9±7.1 41.9±12.2 20.1±9.0 25.1±8.8 17.5±4.1
p<0.001 p<0.001 p<0.02
AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; GGT, γ-glutamyl transpeptidase; NS, not 
significant
Tab. 2. The concentration of  hyaluronic acid (HA), aminoterminal propeptide of type III procollagen (PIIINP), and tissue inhibitor of matrix 
metalloproteinase type 1 (TIMP-1) as well as ELF test in obese children in relation to gender and present of steatosis.
ELF test 
All children Boys Girls
With steatosis Without steatosis With steatosis Without steatosis With steatosis Without steatosis
HA 18.2±8.4 12.1±6.2 20.4±10.6 12.0±6.4 16.7±6.7 12.2±6.2
p<0.003 p<0.02 NS
PIIINP 19.4±8.9 17.0±8.2 19.0±9.7 17.0±8.2 19.6±8.7 16.9±8.5
NS NS NS
TIMP-1 246.1±35.5 220.8±38.3 266.6±41.7 225.2±36.6 232.4±23.7 216.5±40.4
p<0.02 p<0.02 NS
ELF 8.98±0.61 8.49±0.57 9.07±0.79 8.51±0.44 8.94±0.48 8.48±0.69
p<0.005 p<0.04 NS
HA, hyaluronic acid; PIIINP, aminoterminal propeptide of type III procollagen; TIMP1, tissue inhibitor of matrix metalloproteinase type 1; NS, 
not significant
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The increasing prevalence of obesity not only in adults 
but also in children and adolescent is the main reason 
for searching new markers of early detection of liver 
steatosis. Evaluation of hepatic steatosis in children is 
usually performed by USG, however interpretation of 
USG results is very difficult, especially in obese chil-
dren (Shannon et al. 2011). Thus, indirect tests and/or 
new test for assessment of the presence of liver fibrosis 
are used for clinical diagnosis. 
One of the predictors of NAFLD, particularly 
of NASH, routinely measured in obese patients is 
increased activity of AST and ALT (Papandreou et al. 
2007). Both enzyme are under influence of many pre-
analytical factors like non-fasting samples, physical 
activity, hemolysis, freeze/thaw serum cycle, etc. It is 
known that in large number of children with NAFLD 
and NASH serum AST and ALT activities can be within 
reference range (Shannon et al. 2011; Angulo 2002; 
Mofrad et al. 2003). It was shown that increased activi-
ties of serum AST and GGT (Patton et al. 2008) or only 
AST activity can be not only a significant predictors of 
NAFLD but also it correlate with the stage of fibrosis so 
that might be use to distinguish significant fibrosis from 
no or mild fibrosis (Carter-Kent et al. 2009). In the pres-
ent study significantly higher AST, ALT, LDH and GGT 
activity in children with US proven steatosis as com-
pared to children without steatosis has been confirmed. 
However, when sex was taken into consideration it 
appeared that significantly higher AST and ALT activ-
ity was confirmed only for boys with steatosis but not 
in girls. This could be in agreement with the hypothesis 
that estrogen can be potentially liver-protective and 
androgens may aggravate NASH (Lobanova et al. 2009; 
Xu et al. 2004). No such differences were observed for 
GGT, as this enzyme was significantly higher both in 
boys and in girls with US proven steatosis. It was found 
that mildly elevated GGT activity does not reflect the 
severity of steatosis or fibrosis in patients with NAFLD 
(Shannon et al. 2011). 
The ELF test is one of noninvasive tests used for 
assessing liver fibrosis stage which could be performed 
in children. This test includes a measurement of three 
extracellular matrix components: HA, PIIINP and 
TIMP-1. In the present study, the concentration of two 
ELF test components, HA and TIMP1, were signifi-
cantly higher in obese children with steatosis as com-
pared to obese children without steatosis. It was shown 
that HA, the most investigated direct marker for liver 
fibrosis, is a good marker to predict liver fibrosis in 
children with the cut-off value for NAFLD 19.1 ng/ml 
and AUC 0.672 (Lebensztejn et al. 2011). In the present 
study the cut off value for discriminating obese children 
with steatosis and obese children without steatosis was 
established at 19.9 ng/ml with AUC 0.742. 
According to the published studies, the ELF test can 
be a good predictor of hepatic fibrosis not only in adults 
patients but also in children: suggested by Nobili et al. 
cut off value for ELF test in children was established at 
the value of 10.51 (Nobili et al. 2009b). Our cut off value 
of ELF test for discriminating obese children with and 
without steatosis was set up at 9.32, with AUC 0.720. 
Similar to AST and ALT activity, also for ELF test values 
the difference between obese boys and obese girls has 
been observed. Significantly higher ELF test value was 
found for obese boys with steatosis as compared to 
obese boys without steatosis. 
The combination of single tests results did not 
improved prediction of the presence of steatosis among 
obese children in the present study. Also, according to 
other studies, no single clinical or laboratory param-
eters reflect the presence or severity of hepatic fibrosis 
in children with NAFLD except for significantly differ-
ent values of BMI (Yang et al. 2012). However, looking 
at the results obtained in the present study, the clear cut 
trend towards higher increase in activity of AST, ALT, 
GGT, HA concentration as well as ELF test value has 
been seen in children with steatosis and showed good 
agreement with US examination. It is well known, that 
Tab. 3. Cut-off values, area under ROC curves, sensitivity, specificity, positive and negative predictive values for liver enzymes, hyaluronic 
acid (HA), aminoterminal propeptide of type III procollagen (PIIINP), tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1) and ELF 
test. 
  Cut-off AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%)
AST (U/L) 33.2 0.704 50.0 92.1 76.9 77.8
ALT (U/L) 55.9 0.670 35.0 94.7 77.8 73.5
LDH (U/L) 393.7 0.692 61.5 84.2 72.7 76.2
GGT (U/L) 26.9 0.804 66.7 91.3 83.3 80.8
HA (ng/ml) 19.9 0.742 40.0 92.1 72.7 74.5
PIIINP (ng/ml) 33.0 0.586 15.0 94.7 60.0 67.9
TIMP1 (ng/ml) 276.0 0.695 15.0 97.4 75.0 68.5
ELF 9.36 0.720 35.0 94.7 77.8 73.5
AUC, area under receiver operating curve; PPV, Positive Predictive Value; NPV, Negative Predictive Value
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finding a good, single marker of early stage of any dis-
ease is almost impossible due to inter- and intraindivid-
ual variations and preanalytical and analytical factors 
affecting clinical chemistry measurement. 
CONCLUSION
ELF test cannot be used for assessment of steatosis in 
obese children.
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